CUMULATIVE INDEX 1992

Volume 21

March	REPRODUCTIVE ENDOCRINOLOGY, pages 1–198
June	DIABETES MELLITUS: PERSPECTIVES ON THERAPY, pages 199–482
September	ACROMEGALY, pages 483–765
December	NEUROENDOCRINOLOGY I, pages 767–950

Note: Page numbers of article titles are in **boldface** type

Abortion, spontaneous, postendometrial biopsy, 95
Acanthosis nigricans, in hyperandrogenism-insulin resistance of PCOD, 144–146, 148
  incidence of, 146
Acarbase, 344–345, 355
Acromegaloidism, in gigantism, 641
Acromegalya. See also *Ectopic acromegaly; Pituitary acromegaly.*
  arthropathy in, 618–624
  bone and mineral metabolism in, 624–625
  clinical manifestations of, **597–614**
    from GH hypersecretion, 601–609
    from hormone oversecretion, 597–598
    from tumor mass, 597–601
    mode of presentation in, 597–598, 600
  clinical presentation of, 649–650
  diagnosis of, **649–668**
    endocrine tests in, 650–652. See also *Endocrine test(s).*
  ectopic, **575–595**
  effects of, 755–756
  etiology of, 649
  growth hormone in, clinical actions of, **519–537**
    increase in, 805–807
    secretion and action of, **483–517**
    studies of, 616–618
  hyperinsulinemia in, 662–663
  living with, **753–760**
  McCune–Albright syndrome in, 625–627
  patient reaction to, at diagnosis, 756–757
    octreotide therapy and, 757–758
    postadenomectomy, 757
  personality changes in, 753–756
  pituitary, etiology of, **539–551**
    gigantism and, **633–647**
    pathology in, **553–574**
  rheumatologic and skeletal changes in, **615–632**
  surgery in, **669–692**
    anesthesia for, 674–675
    complications of, 681
    failure management of, 686–688
    history of, 669–670
    indications for, 670
    medical pretreatment for, 672–673
    perioperative management of, 681–682
    preoperative evaluation for, 670–672
    results of, 682–687
    transcranial approach in, 674, 681
    transsphenoidal adenomectomy, 673–680
  treatment of, dopamine agonists in, **713–735**
    radiotherapy in, **693–712**
    somatostatin analogs in, **737–752**
    surgery in, **669–692**
ACTH. See *Adrenocorticotropic hormone (ACTH).*
Adenectomy, transsphenoid, 673–680, 886–888
Adenoma(s), acidophil stem cell, pathology of, 557–560

Adenoma(s) *(Continued)*
tissue culture of, 566
bromocriptine effect on, 893–894
in hyperprolactinemia, treatment of, 113–114
mammosomatotroph, 557–560
plurihormonal, acidophil cell line, 557–560
unusual, 560–561
somatotroph, etiology of, 555–557
therapy for, 565–566
tissue culture of 562
pituitary, GH-secreting, 672–673
in gigantism, 640
somatostatin receptors on, 737–739
somatotroph-lactotroph, etiology of, 557
transsphenoidal surgery for, 886–888
Adenomectomy, transsphenoid, 673–680
closure in, 679
complications of, 679, 681
hypophysectomy in, 679
midline approach in, 676–677
paraseptal approach in, 676–687
patient reaction to, 757
pituitary function following, 686
positioning for, 676
pre- and postoperative images in, 678, 680
results of, 683–686
tumor curettage in, 678–679
Adrenal insufficiency, HPA axis in, 848
Adrenocorticotropic hormone (ACTH), CRH regulation of, 836–849
in disease states, 847–849
in normal states, 845–847
Aging, GH deficiency in, neuroendocrine mechanisms in, 801
secretory rates and body composition in, 800–803
therapeutic potential and, 801–802
neuroendocrinology of, **921–931**
cortisol axis and, 926–927
in andropause, 924–925
in menopause, 921–924
prolactin and, 917
thyroid axis and, 925–926
vasopressin and, 917–918
Alkylating therapy, hypergonadotropic amenorrhea from, 179–180
Amenorrhea, athletic, 818–819
exercise training and, 818
hypergonadotropic, **173–191**
autoimmune disturbances in, 180–183
bone loss in, 176
enzymatic defects in, 179
estrogen deficiency symptoms in, 175
estrogen replacement in, 185–186
evaluation of, 184–185
from chemotherapy and radiation, 179–180
genetic and cytogenic alterations in, 177–179
gonadotropin defects and failure in, 183–184
idiopathic, 184
immune abnormalities in, 175–176
oocyte donation pregnancy and, 186–188
ovulation induction in, 175–176
progestin-induced withdrawal bleeding in, 176
viral causes of, 180
hypothalamic, GnRH therapy for, 131
in young women, **173–191**
polycystic ovaries and, 160
Androgen, plasma, insulin levels and, 143
suppression of, in hyperandrogenic patient, 59–60
Andropause, GH therapy for, 925
signs and symptoms of, 924
testosterone decrease in, 924–925
Androstenedione, plasma, insulin levels and, 143–145
Angiogenesis, in follicular fluid, 31–32
Angiotensin II, in prolactin stimulation, 106
Anovulation, in PCOD, 141
therapy for, 59
Antihypertensive therapy, in IDDM, 382–384
in NIDDM, 385–386
Arginine test, for acromegaly, 660
Arthropathy, acromegalic, arthritides associated with, 624
clinical signs of, 618
degenerative, 619–623
pathophysiology of, 618
response to therapy in, 623
Atherosclerosis, in diabetes mellitus, 239
age and sex in, 395
lipid abnormalities in, 396
risk of, from insulin therapy, 362
in diabetes, 374–375
Autoantibody(ies), in IDDM, insulin, 205–206
islet cell, 204–205
Autoantigens, in IDDM, 206–207
Autoimmune diseases, endocrine, 175–176, 180–182
HLA-DR 3 and, 182
in hypergonadotropism amenorrhea, 175–176
leukocyte migration inhibition factor in, 182
lymphocytic infiltrates and, 181–182
thymic aplasia in, 182–183
AVP. See *Vasopressin*.

Basal body temperature (BBT), in ovulation detection, 44–57
devices for, 45–46
Basic fibroblast growth factor (bFGF), 7
BBT (basal body temperature), in ovulation detection, 44–57
devices for, 45–46
Beta blocker therapy, in diabetic patient, 385–386
bFGF (basic fibroblast growth factor), 7
Biguanides, 344–345, 355
Binding proteins, in GH secretion, in circulation, 497–498
Biopsy, endometrial, 94–95
ovarian, for hypergonadotropic amenorrhea evaluation, 185
Bleeding, abnormal, GnRH agonist therapy for, 137
withdrawal, in hypergonadotropic amenorrhea, 176
Blood basophil count, in ovulation detection, 52
Bone, loss of, from GnRH agonist therapy, 134–135
in hypergonadotropic amenorrhea, 176, 185
metabolism in, of GH and IGF–1, 616–618, 624–625
Bradykinin, in ovulation, 30
Brain, necrosis of, radiation-induced, 706
Breast feeding, hyperprolactinemia management in, 119
Bromocriptine, adverse reactions to, 62, 115–118
comparison with octreotide, 746
effects of, clinical improvement, 722–723
efficacy, 720–721
GH and IGF–1 suppression, 719–720
hypothalamic, 716–717
normoprolactinemia, 888–889
on adenomas, 893–894
on fetus, 892
on hormone testing, 720
on metabolic and clinical parameters, 720–722
on sperm motility, 116–117
on tumors, 723–724
perivascular fibrosis, 890
pituitary, 716–717
prolactin reduction, 889–890
tumor reduction, 890–891
efficacy of, 720–721
for acromegaly, 719–726
for hyperprolactinemia, 61–62, 112–118, 120
during pregnancy, 117–118
with infertility, 114–117
for PCOD, 153–154
in combination therapy, 725–726
management of, in pregnancy, 893–894
pharmacology of, 717–718
dosing of, 719
safety of, 719
side effects of, 718–719
postadenomectomy, 688
response to, predictors of, 724–725
routes of administration for, 891
side effects of, 891
Bromocriptine test, for acromegaly, 659–660
for gigantism, 644–645
Buserelin, for endometriosis, 133–134

Cabergoline, for acromegaly, 726–727, 892
CAD. See *Coronary artery disease.*
Calories, in diabetic diets, 243–244
Captopril, 344
Carbohydrates, effects of, high density lipid reduction, 252–253
hypertriglyceridemia, 252–253
insulin sensitivity, 253
metabolism of, protein intake and, 265–266
Carcinomas, in pituitary acromegaly, 561
Cartilage, metabolism in, of GH and IGF–1, 616–618
physiology of, 615–616
Central nervous system (CNS), radiation injury to, 702–703
Cerebral spinal fluid (CSF), leakage of, in transsphenoid adenomectomy, 679, 681
Cervical mucus, in ovulation detection, enzymes in, 49–50
properties of, 46–49
protein constituents of, 49
volume of, 50
Chaosx. See *Insulin-resistance syndrome.*
CHD (coronary heart disease), risk of, 375–376
CHF. See *Congestive heart failure (CHF).*
Chylomicronemia syndrome, 399–400
Clomiphene citrate, for anovulation, chronic, 59
for luteal phase defect, 97–98
for ovulation induction, 33, 62–68
adverse reactions to 66–67
contraindications to, 64
dosage and administration of, 64–65
indications for, 63–64
monitoring of, 66–67
pharmacology and mechanism of action of, 62–63
results of, 67
for PCOD, 151–152

Clomiphene citrate *(Continued)*
for unexplained infertility, 76–78
CNS (central nervous system), radiation injury to, 702–703
Congestive heart failure (CHF), in diabetes mellitus, 381
Coronary artery disease (CAD), in diabetes mellitus,
hyperinsulinemia in, 242
lipids in, 240–241
triglycerides in, 239–240
Coronary heart disease (CHD), risk of, in diabetes, 375–376
Corpus luteum, deficiency of, exercise and, 818
in ovarian function, 20–21, 23
LH surge in, 28–29
in luteinization, 32
Corticotropin-releasing hormone (CRH), actions of, in stress response, 834
with glucocorticoids, 835–836
with locus ceruleus/norepinephrine system, 834–835
discovery of, 833–834
stimulators of, 837
types of, hypothalamic, 833
immune system, 841–844
placental, 840–841
Cortisol, in diabetic pregnancy, 434–435
Cortisol axis, aging and, ACTH and, 926
cortisol secretion in, 926
dehydroepiandosterone sulfate (DHEA-S) decrease in, 926–927
CRH. See *Corticotropin-releasing hormone (CRH).*
CSF (cerebral spinal fluid), leakage of, in transsphenoid adenectomy, 679, 681
Cushing's disease, pituitary, 847–849

DA. See *Dopamine (DA).*
DCCT. (Diabetes Control and Complications Trial) Research group, insulin-induced hypoglycemia study, 314–315, 323
DDAVP (desmopressin), for SIADH, 863–864
Dehydroepiandosterone sulfate (DHEA-S), decrease of, 926–927
insulin levels and, 146
Demeclocycline (demeclocyclin), 873
Demeclycyclin (Demeclocycline), 873
Desmopressin (DDAVP), for SIADH, 863–864
DHEA-S. See *Dehydroepiandosterone sulfate).*
DHEA:testosterone ratio, in insulin resistance, 143, 146
Diabetes Control and Complications Trial (DCCT) Research group, insulin-induced hypoglycemia study, 314–315, 323
Diabetes mellitus. See also *Insulin-dependent diabetes (IDDM); Noninsulin-dependent diabetes mellitus (NIDDM).*
classification of, 329–330
complications of, atherosclerosis, 374–375
congestive heart failure, 381
coronary artery disease, 375–376
nephropathy, 377–380, 386–387, 442–443, 446
neuropathy, 228, 262–263, 280, 380, 387–388
retinopathy, 380
diets for, **237–270**
DKA-hyperosmolar coma in, **415–432**
glucose control in, **221–235**
hyperlipidemia in, **395–414**
hypertension in, **371–394**
in acromegaly, **313–327**, 643
in pregnancy, **433–456**
insulin-dependent vs. noninsulin-dependent, 329–330, 351–352
insulin-resistance syndrome in, **329–350**
insulin therapy for, **281–311**, 461–467
pathogenesis, prediction, prevention of, **199–219**
perioperative management of, **457–475**
sulfonylurea treatment failure in, **351–370**
treatment of, **199–414**
type I vs. type II, 329–330
Diabetic diet(s), **237–279**. See also *Very low calorie diets (VLCD).*
caloric intake in, 242–251
calorie requirements and, 242–243
very low calorie diets and, 244–251
weight loss controversy and, 243–244
carbohydrates in, fiber and, 254–255, 270
high, 251–253
fats in, 255–256
monosaturated vs. polyunsaturated, 256–260
omega fatty acids in, 260–261
for gestational diabetes, 439–440
for hyperlipidemia, 404–405
for NIDDM, 268–279, 337, 352, 354–355
history of, 237–242
carbohydrates in, 237–239
dyslipidemia and, 239–2411
fasting in, 222, 238
protein intake in, 261–268
glomerular hemodynamics and, 262–264

glomerular hyperfiltration and, 261–262
recommended dietary allowance of, 266
restriction of, 264–267
very low calorie, 244–251
Diabetic ketoacidosis (DKA)-hyperosmolar coma, **415–432**. See also *Osmolarity*.
complications of, hypoglycemia, 429–430
hypokalemia, 429–430
infection, 429
pancreatitis, 429
thrombosis, 429–420
laboratory data in, 420–421
pathogenesis of, hyperosmolar coma in, 416
ketoacidosis in, 415–416
precipitating factors in, 417–419
signs and symptoms of, 419–421
hyperglycemia and, 421–422
hyperosmolarity and, 422–425
treatment of, assessment of, 427
bicarbonate in, 429
fluid replacement in, 425–427
insulin in, 425, 427–428
phosphate in, 428–429
Diuretic therapy, for diabetic patient, 375–376, 383, 387
thiazides in, 385–386
See *Diabetic ketoacidosis (DKA)-hyperosmolar coma*.
Dopamine (DA), deficiency of, in PCOD, 148
in prolactin inhibition, 105–106, 877–878
Dopamine agonist(s), **713–735**
for acromegaly, bromocriptine, 719–726
cabergoline, 726–727, 892
lisuride, 726
mesulergine, 726
paradoxic response to, 717
pergolide mesylate, 726
terguride, 726
for ectopic acromegaly, 588
for gigantism, 644–645
for somatotroph adenomas, 565
normal GH secretion and, central effects of, 715
physiology of, 714
pituitary effects of, 716

Eating disorders, in PCOD, 142–143
Ectopic acromegaly, **575–595**
clinical features of, 584–585
epidemiology of, 583
imaging of, 586–587
laboratory findings in, 585–586
pathogenesis of, 576–579
GH-producing tumor in, 579
GHRH-producing tumor in, 576–578
pathology of, 579–582
GH-secreting tumors, 582
in GHRH-producing tumor, 579–581
pituitary lesions, 581
secretory products in, GHRH, 582–583
peptides, 583
treatment of, cytotoxic chemotherapy in, 587–588
surgery in, 587
Education, of pregnant diabetic women, 448
EGF/TGF-α. See *Epidermal growth factor/transforming growth factor-α (EGF/TGF-α)*.
Endocrine disorders, in hypergonadotropism, 175–176
Endocrine tests, for acromegaly, 650–662
arginine, 660
bromocriptine, 659–660
GH, 650–653
GHRH, 656–657
IGF-binding proteins, 661–662
insulin-induced hypoglycemia, 661
L-dopa, 659
luteinizing hormone releasing-hormone, 661
oral glucose tolerance test, 653
somatomedin C/insulin-like growth factor, 653–656
somatostatin, 660
TRH stimulation, 657–659
type 111 procollagen propetide, 662
values of, 585–586
Endometrial biopsy, in LPD diagnosis criteria for, 94–95
spontaneous abortion risk from, 95
timing of, 94–95
in luteal phase defect diagnosis, 94–95
Endometriosis, GnRH agonist suppression of, 132–135
adverse reactions to, 133–135
with buserelin, 133–134
with nafarelin, 133
with norethindrone, 134–135
Endometrium, biopsy of, in LDP diagnosis, 94–95
in ovulation detection, 50
in menstrual cycle, 87–88
Endurance training, hypothalamic-pituitary axes and, **817–832**. See also *Gonadotropins; Growth hormone (GH)*.
Enteral nutrition, for diabetic patient, perioperative, 470–472
Enzymes, in cervical mucus, 49–50

Epidermal growth factor/transforming growth factor-α (EGF/TGF-α), 5–6
Epinephrine, release of, clinical observation of, 317
factors in, 319
hypoglycemic clamp technique study of, 317–310
in insulin-induced hypoglycemia, 316–317, 319–320
mechanism of, 319
Estradiol, supplemental, in oocyte donation, 187
Estrogen, assays of, in ovulation detection, 43
deficiency of, symptoms of, 175
E2 serum levels, during hCG therapy, 74
during hMG therapy, 68–71
in diabetic pregnancy, 434–435
in GH secretion, 770
therapeutic, for hypergonadotropic amenorrhea, 185–186
Exercise, amenorrhea from, 818–189
in gestational diabetes, 441–442
in insulin-resistance syndrome, 337
requirement for, 441–442
stress of, HPA axis and, 845–847

Fats, effect of, on high density lipid, 257–258, 260
on low density lipid cholesterol, 255–258
on very low density lipid cholesterol, 255, 258, 260–261
Ferning, of cervical mucus, 46–47
Fiber, in diabetic diet, 254–255, 275
Fibric acid, derivatives of, 344–345
Fibroids. See *Leiomyomata, uterine.*
Flurinef, 873
Follicles, atresia of, 26
dominance of, 25–27
formation of, 21
luteal function of, 32
midcycle dynamics of, 26, 28–29
luteinization of, 29
meiosis in, 26, 28–29
recruitment of, 24, 26
rupture of, 29–32
selection of, 24–27
wall of, muscle activity of, 31
proteolytic digestion of, 29–30
Follicle-stimulating hormone (FSH), elevated, therapy for, 58
in menstrual cycle, 39–40, 42, 86–87
in prolactin stimulation, 107
low level of, with normal prolactin level, 59
Folliculogenesis, fetal, 21
gonadotropin-dependent, 22–23, 29
gonadotropin-independent, 21–22
in luteal phase defect, 88–89
intraovarian peptides in, **1–17**. See also *Peptides.*
temporal coordination by, of ovarian events, 22
FSH. See *Follicle-stimulating hormone (FSH).*

GABA (gamma-aminobutyric acid), in prolactin inhibition, 106
Gamete intrafallopian transfer, GnRH agonist/hMG therapy for, 79–80
Gamma-aminobutyric acid (GABA), in prolactin inhibition, 106
GAP. See *Gonadotropin-associated peptide (GAP).*
Genetics, in diabetes mellitus, 201–204, 211, 454
GH. See *Growth hormone (GH).*
GH-BP. See *Growth hormone-binding protein (GH-BP).*
GHRH. See *Growth hormone-releasing hormone (GHRH).*
Gigantism, **633–647**
complications of, 643–644
in GH transgenic animals, 637–638
definition of, 639
diagnosis of, classification in, 642
differential, 642–643
etiology of, 639–641
acromegaloidism in, 641
carcinoid tumors in, 641
GHRH elevation in, 640
McCune-Albright syndrome in, 640
pituitary adenomas in, 639–640
pituitary somatomammotroph hyperplasia, 640
experimental, 635–637
historical overview of, 633–635
physiology of, 638–639
stature in, pathologic, 639–641
physiologic, 638–639
treatment of, bromocriptine in, 644–645
octreotide in, 645
surgical, 644, 645
Glucagon, response of, to hypoglycemia, 316
Glucocorticoids, CRH actions and, 835–836
exogenous, for hyperandrogenism, 59–60
in GH secretion, 489–490
in GH suppression, 804

in stress-related homeostasis, 851–852
Glucose, counterregulation of, 316–320
auditory evoked potentials study of, 319
clamp technique study of, 317–319
clinical observation of, 316–317
enhancement of, 323
mechanism of, 319
epinephrine in, 316–317, 319–320
research in, 323–324
metabolism of, in GH therapy, 531
Glucose control, **221–235**
glucose hypothesis in, 222–223
in IDDM, 223–228
animal studies of, 224–225
human studies of, 225–228
in NIDDM, costs of, 231
effects of, 229–230
risks of, 230–231
Gonadal hormones, in GH secretion, 491–492
Gonadotropin agonist therapy, ovulation induction by, 34
Gonadotropin-associated peptide (GAP), prolactin and, inhibition of, 877–879
stimulation of, 107
Gonadotropin-binding inhibitors, 10
Gonadotropin-releasing hormone (GnRH), **125–140**
analogs of, 126–127, 129
clinical uses of, for delayed puberty, 132
for endometriosis, 132–125
for hirsutism, 136–137
for hormone-dependent tumors, 136
for ovulation induction, 130–132
for precocious puberty, 132
for uterine leiomyomata, 135–136
diagnostic use of, 129
for ovulation induction, hCG support with, 74, 130–131
monitoring of, 74–75
pulsatile administration of, 73–74
results of, 75–76
GH induction and, 773, 775
in menstrual cycle, 86
in prolactin stimulation, 107
physiology of, gonadotropin secretion and, 127–129
LH pulsation and, 128
progesterone secretion and, 128–129
properties of, agonistic, 126–127
antagonistic, 126–127
with hCG, for in vitro fertilization, 79–80
with hMG, for in vitro fertilization, 79–80
Gonadotropin(s), exercise and, in amenorrheic women, 818–819
for folliculogenesis, 21–23, 29
for LPD, hCG, 98–99
hMG, 98–99
for ovulation induction, 34–35
for PCOD, FSH, pulsatile, 158
GnRH, 158–159
GnRH agonists and, 156–157
hCG, 159
hMG vs. pure FSH, 157–158
rationale for, 155–156
regimens for, 156
vs. clomiphene citrate, 159
in athletic women, 818–821
CRH and, 820
GH levels in, 821
GnRH and, 820–821
opiate peptides and, 821
pulsatile LH levels and, 818–820
in central hypothyroidism, 909–910
in long-distance women runners, 821–825
FSH in, 824
pulsatile LH in, 823–825
response to exogenous GnRH and, 824–825
study protocol and, 822–823
Growth hormone (GH). See also *Somatotropic axis.*
actions of, 504–508
GH receptor in, 499–504
growth promotion, 505–506
IGF–1 generation, 504–505
on metabolism and composition, 507
antibodies to, post-GH therapy, 532
axis of, pubertal changes in, 771–775
GnRH induction study, 773, 775
IGF–1 levels and, 772–774
testosterone induction study, 773
central regulation of, GHRH and somatostatin integration of, 487–488
neurotransmitters and neuropeptides in, 486–487
clearance of, 789–790
clinical pathophysiology of. See also named factor in, e.g. *Aging.*, 795–807
control of, 783–784
deficiency of, differential diagnosis of, 783–784
drug-induced, 804
from structural lesions, 796
glucocorticoid-induced, 804
in aging, 800–804
in obesity, 797–800
in puberty, 777–778
pubescent and prepubescent, 777–778
free, 789, 792–793
24-hour pattern of, 485–486

Growth hormone (GH) *(Continued)*
hypersecretion of, effects of, acral, skin, bone changes, 603
cancer, 606–608
carbohydrate intolerance, 604
cardiac disease, 605–606
hypertension, 604
mortality, 601–603
neuromuscular and psychiatric, 606
parathyroid dysfunction, 609
respiratory, 608
thyroid dysfunction, 609
radiotherapy for, 694–699
increase in, in acromegaly, 805–807
metabolic clearance of, 791–795
GH-BP and, 794–795
half-life in, 793–795
in men, 794
of bound versus free GH, 792–793
physiologic conditions and, 793–794
peripheral signals in, 488–494
hormonal, 488–492
metabolic fuels, 492–494
plasma levels of, octreotide effect on, 740–745, 746
protein-bound, 789
pulsatile release of, in endurance training, 826–828
in pathophysiologic conditions, 827
secretion and action of, **483–517**
central regulation of, 486–488
gender and sex steroid effect on, 804–805
GH-releasing hormone in, 784
24-hour pattern of, 485–486
in acromegaly, 805–807
in children, 768–770
in circulation, 497–421, 497–499
inhibition of, 795–797
in obesity, 797–800
nutrition factors and, 788–789
peripheral signals in, 488–494
postadenomectomy, 683
sleep and, 786–788
somatostatin in, 784–785
with GH-RH, 784–786
somatotroph cell in, 495–497
stimulation of, 796
secretion of, by pubertal stages, 771
estrogen and, 771
GHRH and, 770–772
gonadotropins and, 767–768
studies of, in chondrocytes, 616–617
in osteocytes, 617–618
therapeutic, **519–537**
complications with, 531–532
effectiveness of, 521–522
historical overview of, 519–520
in adults, 523–529
GH-deficient, 523–525
malnourished, 524
non-GH-deficient, 524, 526
obese, 528–529
postoperative and burns, 524, 527
in children, 521–523
female with Turner syndrome, 521–522
GH-deficient, 521
short, 522–523 with miscellaneous syndromes and metabolic disorders, 523
with renal failure, chronic, 523
with rickets, x-linked hypophosphatemic, 523
patient expectations of, 532
possible effectiveness of, 522–523
practical aspects of, 532
response to, 520–521, 528, 531
evaluation of, 520–521
somatostatin and, in puberty, 770
speculative uses for, 523–530
tissue resistance to, 789
transport of, GH-binding protein and, 781–791
Growth hormone (GH) receptor, actions of, 499–504
gene expression of, 501–502
GH-BP in, 499–500
in Laron's syndrome, 500–501
intracellular signalling, 503–504
on GH-prolactin-cytokine family, 501
target tissue association of, 502–503
GH clearance and, 792
somatomedin hypothesis of, 795
Growth hormone (GH) test, for acromegaly
basal level in, 650–651
24-hour circadian sampling, 651–652
urinary measurements in, 653
Growth hormone binding protein (GH-BP), GH receptor and, 792
metabolic clearance of GH and, 792, 794–795
transport of GH and, 789–791
Growth hormone releasing-hormone (GHRH) test, for acromegaly, 656–657
in gigantism, 640
in pituitary acromegaly, hypothalamic, 545–546

hCG. See *Human chorionic gonadotropin (hCG).*
hCS (human chorionic somatomammotropin), 434–435
HDL. See *High density lipid (HDL).*

Hemoglobin, glycosolated, in pregnant diabetic women, 449–450
hGH (human growth hormone), postadenectomy, 682
High density lipid (HDL), effect on, of carbohydrates, 252–253
of fat, 256–268, 260
in diabetes mellitus, reduction of, 240–241
Hirsutism, GnRH therapy for, 136–137
in polycystic ovary disease, 141–142
Histamine, in ovulation, 30
hMG. See *Human menopausal gonadotropin.*
HPA. See *Hypothalamic-pituitary-adrenal (HPA) axis.*
hPL (human placental lactogen), 434–435
Human chorionic gonadotropin (hCG), for LPD, 98–99
in in vitro fertilization, 78
ovulation induction by, 33, 35
Human chorionic somatomammotropin (hCS), 434–435
Human growth hormone (hGH), basal, postadenomectomy, 682
Human menopausal gonadotropin (hMG), for LPD, 98–99
for ovulation induction, 74, 79–80
for unexplained infertility, 76–78
Human placental lactogen (hPL), 434–435
Hyaluric acid, in ovulation, 30
Hydroxychloroquine, 345
Hyperandrogenism, causes of, 143
treatment of, 59–60
Hyperandrogenism-insulin resistance, hyperandrogenism in, 143–144
in PCOD, 143–146
insulin resistance in, 144–145
Hyperglycemia, complications from, 282
effect of, on pregnancy, 436
in DKA-hyperosmolar coma, 421–422
rebound,in pregnant diabetic women, 450
Hypergonadotropinism, amenorrhea in, **173–191**. See also *Amenorrhea.*
Hyperinsulinemia, in acromegaly, 662–663
sympathetic activation of, 373
Hyperlipidemia. See also *Lipids; Lipoproteins.*
in diabetes mellitus, management of, **395–414**.
lipid and lipoprotein profile in, 402–404
treatment of, dietary, 404–405
pharmacologic, 405–407
with fibric acids, 406
with HMG CoA reductase inhibitors, 405–406
with niacin, 405–407
triglyceride profile in, 403
Hyperosmolar coma. See also *Diabetic ketoacidosis (DKA)-hyperosmolar coma syndrome.*
Hyperosmolarity. See also *Osmolarity.*
in DKA-hyperosmolar coma syndrome, 422–425
Hyperplasia(s), in gigantism, 640
in pituitary acromegaly, mammosomatotroph, 561, 564
somatomammotroph, 561–563
tissue culture of, 567
Hyperprolactinemia, **105–128**. See also *Prolactinoma(s).*
causes of, 109
evaluation of, 60–61
associated clinical conditions and, 110–112
isotypes and, 109–110
radiographic imaging in, 110–112
radioimmunoassys variations in, 110
functional, 112–113
GnRH agonist therapy for, 137
pathologic, 881–887
diagnostic testing for, 885–886
from antihypertensives, 882
from ectopic secretion, 883
from hypothalamic/pituitary stalk disease, 883–884
from prolactinomas and secretory tumors, 884–885
from psychotropic medications, 881
idiopathic, 884
in adrenal insufficiency, 883
in cirrhosis, 882
in hypothyroidism, 882–883
in renal disease, 882
neurogenic, 883
post-transsphenoidal surgery, 887–888
physiologic, 880–881
postmenopausal management of, 119–120
prolactin secretion in, inhibition of, 105–106
ovarian function and, 108–109
stimulation of, 106–107
treatment of, 60–61
bromocriptine in, 61–62, 112–113
in infertility, 114–117
in pregnancy, 117–118
macroadenomas and, 113–114
microadenomas and, 113
postpartum, 118
Hypertension, in diabetes mellitus, management of, **371–394**
in gestational diabetes, 443–446
in IDDM, 381
epidemiology of, 381–382
treatment of, 382–384

Hypertension *(Continued)*
in NIDDM, epidemiology of, 384–385
treatment of, 385–386
Hyperthyroidism, central hypothyroidism following, 914–916
Hypertriglyceridemia, carbohydrate-induced, 252–253
in diabetes mellitus, 239–240
in NIDDM, 252
Hypoestrogenism, FSH elevation in, 58
Hypoglycemia, clinical implications of, 322–323
counterregulatory hormone release in, 315–320
diagnostic, for acromegaly, 661
drugs for, actions of, pancreatic and extrapancreatic, 338–341
insulin-sparing, acarbase, 344–345, 355
captopril, 344
fibric acid derivatives, 344–345
hydroxychloroquine, 345
metformin, 344–345, 355
sulfonylureas, 338–344, 352–354
GH deficiency-associated, 521
in IDDM, counterregulatory hormone release in, 316–320
defective glucose counterregulation in, 315–316
risk of, 314–315, 320, 322
in NIDDM, 360–361
insulin-induced, **313–327**. See also *Glucose*.
risk of, physiologic and metabolic, 320
incidence of, 314–315
reduction of, 322–323
Hypogonadism, hypogonadotropic, hMG therapy for, 68–69
idiopathic, 131–132
Hypokalemia, DKA-hyperosmolar coma syndrome and, 418, 429–430
Hypopituitarism, radiation-induced, 703–704
Hypotension, in diabetic autonomic nephropathy, 387–388
Hypothalamic-pituitary-adrenal (HPA) axis, **833–858**
clinical studies of, 845–849
exercise stress and, 820, 845–847
in disease states, adrenal insufficiency, 848
atypical seasonal depression, 849
premenstrual tension syndrome, 848–849
psychiatric disorders, 848
pituitary Cushing's disease, 847–849
in normal states, dynamic exercise stress, 845–847
stress of surgery, 845–846
regulation of, 836–845
CRH in, hypothalamic, 838–839
immune, 841–844
placental, 840–841
in Lewis rat, 844–845
research hypotheses and, CRH agonists and antagonist therapies, 851
glucocorticoids in stress-related homeostasis, 851–852
hypothalamic CRH hyper-and hyposecretion in stress states, 849–850
response in autoimmune/inflammatory disease, 850
Hypothalamic-pituitary axes, endurance training and, **817–832**. See also *Gonadotropins; Growth hormone (GH)*.
Hypothalamic-pituitary-gonadal function, GnRH diagnosis of, 129
Hypothalamic/pituitary stalk disease, hyperprolactinemia in, 883–884
Hypothalamus, hypothyroidism and, from TRH deficiency, 907–908
in pituitary acromegaly, etiology of, 544–546
pathogenesis of, 541
Hypothyroidism, central, **903–919**
animal models of, 913–914
basal thyroid stimulating hormone in, 909–912
causes of, 905–908
following hyperthyroidism, 914–916
from GH therapy, 531
from pituitary disease, 905–906
from pituitary hormone deficiency, 909–910
from TSH deficiency, 906–907
hypothalamic cause of, 907
iatrogenic, 907–908
laboratory findings in, 909–913
signs of, 908
symptoms of, 908–909
TRH deficiency in, 907
TRH stimulation tests in, 912–913
treatment of, 913
versus primary, 903, 911
GH deficiency in, 804
hypothalamic, causes of, 907
TRH deficiency in, 907–908, 913

IDDM. See *Insulin-dependent diabetes mellitus (IDDM)*.
Idiopathic hypogonadotropic hypogonadism (IHH), GnRH therapy for, 131–132
IGF-BP (insulin-like growth factor-binding protein) test, for acromegaly, 661–662

IGF–1. *See* Insulin-like growth factor (IGF–1).
IHH (idiopathic hypogonadotropic hypogonadism), 131–132
IL–1 (Interleukin–1), 7–8
Immune system, in diabetes mellitus, 207–208
Immunohistochemistry, in LPD diagnosis, 95–96
In vitro fertilization (IVF), GnRH agonist/hCG protocol for, 7880
GnRH/hMG protocol for, 131–132
Infection, DKA-hyperosmolar coma syndrome and, 418, 429
in gestational diabetes, 446–447
in hypergonadotropism, 176
Infertility, therapy of, in hyperprolactinemic patient, 114–117
unexplained, clomiphene citrate therapy for, 76–77
hMG therapy for, 76–78
Insulin, physiologic, action and secretion of, 332–333
degradation of, during pregnancy, 435–436
food intake and, 283–286
plasma androgen levels and, 143
plasma glucose levels and, 284–285
resistance to. See also *Insulin-resistance syndrome (syndrome X)*,
in PCOD, acanthosis nigricans in, 144–145
DHEA:testosterone in, 143–144
obesity and, 144–145
therapeutic, combined with sulfonylurea drugs, 363–365
delivery methods for, 293–294
drip, 466–467
infusion, 465–468
pump, 294, 308, 310–311
subcutaneous, 288–289, 292
human, for pregnant diabetic women, 450
hypertension from, 373–374
in IDDM, **281–311**
delivery methods for, 293–294
goals of, 283
initiation of, 307–311
physiologic insulin secretion and, 283–286
pump allocation of, 310–311
rationale for, 282
regimens for, 294–298, 307
subcutaneous, pharmacology of, 286–293
in NIDDM, adverse effects of, 360–362
dosing of, 358–359
evening-only administration of, 359–360
intermittent, 360
mechanism of action of, 355–356
preparations for, 3356–357
perioperative, delivery of, 465–467
during enteral and parenteral feeding, 470–472
in ambulatory surgery, 468–469
indications for, 461–462
regimen for, 464–465
requirements for, 462–463
preoperative, 460
requirement for, in diabetic pregnancy, 440–441
in gestational diabetes, 440–441
postpartum, 452
Insulin-dependent diabetes mellitus (IDDM), complications of, atherosclerosis, 374–375, 395–396
coronary artery disease, 375–376
nephropathy, 227–228
neuropathy, 228
retinopathy, 225–227
epidemiology of, 223
in puberty, GH excess in, 778–779
interventional studies of, animal models, 224–225
human, 225–228
interventions in, 211–214
immunostimulants, 213
immunosuppressive agents, 211–212
insulin, 214
insulin antibodies, 213
monoclonal antibodies, 212
nicotinamide, 212–213
NIDDM versus, 351–352
outcome of, 221–222
pathogenesis of, 200–208
autoantibodies and autoantigens in, 204–207
environmental triggers of, 208
genetics in, 201–204
immune system in, 207–208
prediction of, by cell-mediated dysfunction measurement, 210–211
by genetic markers, 211
by islet cell autoantibodies, 209
risk factors in, 223–224
Insulin-glucose infusion, perioperative, 465–468
Insulin-like growth factor–1 (IGF–1), 4–5
effect of, on GH, 789, 795
plasma levels of, octreotide effect on, 743–744, 746
somatomedin hypothesis and, 795
synthesis of, 795
studies of, in chondrocytes, 616–617
in osteocytes, 617–618

Insulin-resistance syndrome (Syndrome X), **329–350**. See also *Hypoglycemic drugs; Sulfonylureas (SUs).*
atherosclerotic vascular disease and, 335
diabetes and, 332–333
dyslipidemia in, 334–335
features of, interrelated, 336
hypertension in, 333–334
in NIDDM, 330–331
management of, 336–346
education and diet in, 337
goals of, 337
insulin-sparing antihyperglycemic drugs in, 344–346
sulfonylureas in, 338–344
Insulin-sulfonylurea therapy, for sulfonylurea failure, 363–365
Interleukin-1 (IL-1), 7–8
IVF. See *In vitro fertilization.*

Ketoacidosis, 415–416. See also *Diabetic ketoacidis (DKA)-hyperosmolar coma syndrome.*

Laron's syndrome, 500–501
LDL cholesterol. See *Low density lipid (LDL) cholesterol.*
L-dopa test, for acromegaly, 726
Leiomyomata, uterine, GnRH therapy for, 135–136
LH. See *Luteinizing hormone (LH).*
LHRH. See *Luteinizing hormone releasing-hormone.*
Lipid(s), abnormalities of, in chylomicronemia syndrome, 399–400
in impaired glucose tolerance, 398
in insulin-dependent diabetes mellitus, 398–399
in non-insulin-induced diabetes mellitus, 397–398
proteinuria and, 399
in diabetes mellitus, high density, 240–241
hypertriglyceridemia and, 239–240
low density, 241
proteinuria and, 399
very low density lipoprotein triglyceride in, 240
metabolism of, protein intake and, 265–266
Lipoproteins, abnormalities of, in impaired glucose tolerance, 398
in NIDDM, 397–398
metabolism of, abnormal, in IDDM, 401–402
in NIDDM, 400–401
Lisuride, for acromegaly, 726
Low density lipid (LDL) cholesterol, effect on, of carbohydrates, 256
of fats, 255–258
in diabetes, 241
LUF (luteinized unruptured follicle) syndrome, during clomiphene citrate therapy, 66–67
Luteal phase defect (LPD), **85–104**
clinical diagnosis of, basal body temperature in, 91–92
endometrial biopsy in, 94–95
progesterone levels in, 92–93
prolactin levels in, 93
ultrasonography in, 93
description of, 88
dietary deprivation and, 91
exercise-induced, 90–91
in fertile women, 89–90
menstrual cycle endocrinology and, 86–88
pathophysiology of, 88–89
research diagnostic methods in, 95–96
treatment of, 96–99
clomiphene citrate in, 66, 97–98
hCG or hMG in, 98–99
progesterone in, 97
Luteinization, in ovulation, in follicular phase, 28–29
in luteal phase, 32
inhibition of, 9
Luteinized unruptured follicle (LUF) syndrome, with clomiphene citrate therapy, 66–67
Luteinizing hormone:follicle-stimulating hormone (LH:FSH) ratio, in PCOD, 149–150
Luteinizing hormone (LH), assays of, in ovulation detection, 42–43, 57
in menstrual cycle, 39–41, 86–87
serum or urinary, 42–43
Luteinizing hormone releasing-hormone (LHRH) test, for acromegaly, 661

Malignancy, radiation-induced, 706–707
McCune–Albright syndrome, in pituitary acromegaly, 546, 625–627
Memory loss, radiation-induced, 707
Menopause, definition of, 921–922
estrogen/progestin paradigms for, 923–924
estrogen replacement for, 922–923
complications of, 923
signs and symptoms of, 922

Menotropins, for ovulation, induction of, 68–73
contraindications to, 69
in anovulation chronic, 59
indications for, 68–69
management of, 69–71
patient evaluation for, 69
results with, 71–73
stimulation of, pre-in vitro fertilization, 78–80
Menstrual cycle, endocrinology of, 86–88
FSH in, 86–87
GnRH in, 86
LH in, 86–87
endometrium in, 87–88
hormone activity during, 39–41
endurance training effect on, 818–819
Mesulergine, for acromegaly, 726
Metabolism, of GH and IGF-1, in bone, 616–618, 624–625
in cartilage, 616–618
Metformin, 344–345, 355

Nafarelin, for endometriosis, 133
Neonate, of diabetic mother, care of, 452–453
Nephropathy, diabetic, hypertension-related, 377–380, 386–387
glycemic control and, 227–228
in gestational diabetes, 442–443, 446
Neuropathy, diabetic, autonomic, 387–388
glycemic control and, 228
hypertension-related, 380
Neurotransmission, in GH regulation, 486–487
in prolactin stimulation, 106–107
Niacin, dietary, for hyperlipidemia, 405–407
NIDDM. See *Non-insulin-dependent diabetes mellitus (NIDDM)*.
Noninsulin-dependent diabetes mellitus (NIDDM), complications of, 228–229
glucose control in, 228–230
effects of, 229–230
risks in, 230–231
hyperglycemia in, oral hypoglycemics for, 338–346
management of, dietary, 268–279, 337, 352, 354–355
in sulfonylurea drug failure, **351–370**
insulin in, 355–362
insulin-sparing hypoglycemics in, 344–346, 355
insulin-sulfonylurea combination in, 363–365
nonpharmacologic, 337, 352, 354–355
sulfonylureas in, 338–344, 352–354
risk factors in, 229
Norethindrone, for endometriosis, 134–135
Nutrition, GH and, endogenous, 788–789
exogenous, 528

Obesity, GH deficiency with, 799–800
in men, 794, 797–798
neurotransmitter role in, 800
primary, 797, 799
somatomedin-C/IGF-1 in, 799
in PCOD, android, 144
hypothalamus and, 150, 152
reduction of, 152
Octreotide (Sandostatin), for acromegaly, **737–752**
comparison with bromocriptine, 746
dosing of, 740, 743–744
effects of, 740–743
response to, 757–758
in, 739–742
selection for, 747–749
side effects of, 746–747
tumor shrinkage with, 744–746
for ectopic acromegaly, 588
for gigantism, 645
for somatotroph adenomas, 565–566
postadenomectomy, 688
somatostatin receptors in, 737–739
OGTT. See *Oral glucose tolerance test*.
OHSS (ovarian hyperstimulation sydrome), with hMG therapy, 70–73
OMI (oocyte maturation inhibitor), 10
Oocyte maturation inhibitor (OMI), 10
Oocytes, donation of donor recruitment for, 186
hormone preparation for, 186
hormone replacement in, 186–187
timing of, 187
Oral contraceptives, for PCOD, 154–155
Oral glucose tolerance test (OGTT), for acromegaly, 653
postadenomectomy, 682
Osmolarity. See also *Hyperosmolarity*.
calculated, 424–425
calculation of, 423–424
Osteoporosis, in acromegaly, 643
Ovarian hyperstimulation syndrome (OHSS), with hMG therapy, 70–73
Ovaries, functions of, 20–21
follicular maturation, 20, 23
luteinization, 20–21, 23
intercellular communication of, 2–3
regulators of, intraovarian, **1–17**. See also under *Peptides*.
Ovulation. See also *Superovulation*.
detection of, **39–55**

Ovulation *(Continued)*
basal body temperature monitoring for, 44–46
blood basophil count in, 52
cervical mucus examination and analysis in, 46–50
electrical resistance in, salivary and vaginal, 53
endometrial biopsy in, 50
hormonal assays for, 41–44
peripheral changes in, 46–53
saliva, steroids in, 51
ultrasound in, 51–52
disorders in, evaluation of, 57–58
types of, 66
induction of, clomiphene citrate in, 33
GnRH in, 130–132
GnRH-hCG combination in, 130–131
gonadotropin agonist therapy for, 34
gonadotropins for, 34–35
hCG in, 33, 35
postlaparoscopic ovarian cautery, 160–161
mechanism of induction and, **19–38**
follicular phase in, 24–27
folliculogenesis and, 21–23
in clinical induction, 33–35
LH surge in, 28–29, 32
mediators in, 30
mucification in, 30–31
muscle activity in, 31
ovarian function in, 20–23
proteolytic digestion of follicular wall in, 29–30
vascularization of granulosa in, 31–32
mediators in, 30
ovarian function in, 20–23
stimulation and induction of, **57–84**
clomiphene citrate in, 59, 61–62, 62–68
GnRH for, 73–76
hMG therapy in, 68–71
menotropins in, 68–73
Oxandrolone, for delayed puberty, 776–777

Pancreatitis, DKA-hyperosmolar coma syndrome and, 429
Parenteral nutrition, for diabetic patient, perioperative, 470–472
Parlodel. See *Bromocriptine.*
PCOD. See *Polycystic ovary disease (PCOD).*
PEP (progesterone-associated endometrial protein) in LPD diagnosis, 96
Peptide histidine methionine (PHM), in prolactin inhibition, 879
Peptide(s), intraovarian, **1–17**
basic fibroblast growth factor, 7
EGF/TGF-α, 5–6
gonadotropin-binding inhibitors, 10
IGF-1, 4–5
interleukin-1, 7–8
luteinization inhibitor, 9
oocyte maturation inhibitor, 10
renin-angiotensin system, ovarian, 10–11
transforming growth factor–225, 6–7
tumor necrosis factor–224, 8–9
Pergolide (Permax), for acromegaly, 726
for prolactinomas 891–892
Perioperative management. See also *Surgery.*
of diabetic patient, **457–475**
enteral and parenteral nutrition in, 470–472
in ambulatory surgery, 468–469
in emergency surgery, 472–473
insulin in, 461–467
postoperative phase, 469
preoperative evaluation in, 4459–461
Permax. See *Pergolide.*
Personality changes, in acromegaly, 753–756
PHM (peptide histidine methionine), in prolactin inhibition, 879
PIFs. See *Prolactin inhibitory factors (PIFs).*
Pituitary acromegaly, etiology of, **539–551**
hypothalamic, 544–546
intrinsic, 541–544
McCune–Albright syndrome in, 546
tumor pathogenesis in, 539–541
pathology of, **533–574**
adenomas, 553–561
carcinomas, 561
hyperplasias, 561–564
in situ hybridization in, 567–568
tissue culture of, 562, 565–567
Pituitary gigantism. See *Gigantism.*
Pituitary tumors, effect on, of bromocriptine, 723–724
Placenta, CRH from, 840–841
GH from, 840–841
PMS (premenstrual tension syndrome), HPA axis in, 848–849
Polycystic ovary disease (PCOD), **141–171**
diagnosis of, ultrasonography in, 141–143
gonadotropin abnormalities in, 147–149
dopamine deficiency in, 148
LH:FSH elevation in, 148
opioid effect on, 148–149
hyperandrogenism insulin resistance in, 143–145
hypotheses for, hyperandrogenism in, 150–151
hypothalamic basis, 150
inhibin, 150
LH:FSH in, 149–150

laparoscopic techniques for, 159–163
endocrine changes following, 162
extirpation, 162–163
techniques in, 161
wedge resection in, 160–162
pathogenesis of, 143–145
treatment of, 151–163
bromocriptine in, 153–154
clomiphene citrate in, 151–152
FSH in, 72
GnRH in, 73, 76–77
GnRH-hMG in, 131
gonadotropins in, 155–159
oral contraceptives in, 154–155
progesterone in, 152–153
weight reduction in, 152
treatment of, 58–59
Precocious puberty, GnRH and, endogenous, 132
exogenous, 778
Pregnancy, diabetic, **433–456**
birth control and, 453–454
delivery in, 451
diabetogenic hormones in, 434–435
diet in, 447–448
education in, 448
glycosolated hemoglobin in, 449–450
human insulin in, 450
hyperglycemia and, effect on, 436, 450
hyperprolactinemia in, 117–118
insulin degradation during, 435–436
labor in, 451–452
maternal complications in, 442–447
normalization program in, 448–449
patient follow-up in, 449
plasma glucose during, 433–434
postpartum management and, 452
gestational diabetes in, definition of, 436
diagnostic criteria for, 438
diet for, 439–440
exercise in, 441–442
insulin for, 440–441
management of, 438–439
screening for, 437–438
multiple, from hCG therapy, 70–71
octreotide effect on, 755–756
oocyte donation for, in hypergonadotropic amenorrhea, 186–188
pregestational diabetes in, 442
prolactin secretion in, 880
rate of, with menotropin therapy, 72
Pregnanediol, assays of, in ovulation detection, 44
Premenstrual tension syndrome (PMS), HPA axis in, 848–849
PRL. See *Prolactin*.
Procollagen propeptide type 111 (P111P) test, for acromegaly, 662
Progesterone, assay of, in LPD diagnosis, 92–93, 95
in ovulation detection, 43, 57
for LPD, 97
for PCOD, 152–153
in diabetic pregnancy, 434–435
supplemental, in oocyte donation, 187
Progesterone-associated endometrial protein (PEP), in LPD diagnosis, 96
PRL. See *Prolactin (PRL)*.
Prolactin (PRL). See also *Hyperprolactinemia*.
elevated, bromocriptine therapy for, 61–62
evaluation of, 60–61
hyperprolactinemia and, pathologic, 881–885
physiologic, 880–881
in diabetic pregnancy, 434–435
inhibition of, dopamine in, 105–106
gamma-aminobutyric acid in, 106
levels of, in LPD diagnosis, 93
physiologic, 880–881
neuroendocrine regulaton of, 877–879
secretion of, 880–881
structure of, 880
secretion of, aging and, 927
circadian, 880
in pregnancy, 880
postpartum, 118
stimulation of, angiotensin II in, 106
FSH in, 107
GAP in, 107
GnRH in, 107
neurotransmission in, 106–107
TRH in, 106–107
vasoactive intestinal peptide in, 106–107
Prolactin inhibitory factor(s) (PIFs), 877–879
dopamine, 877–878
gonadotropin-associated peptide, 877–879
peptide histidine methionine, 879
thyrotropin-releasing hormone, 879
vasoactive intestinal peptide, 878–879
Prolactin releasing factors, 878–880
thyrotropin-releasing hormone, 879
vasoactive intestinal peptide, 878–879
Prolactinoma(s). See also *Adenoma(s)*.
effect of, on pregnancy, 892–893
hyperprolactinemia from, 884–885
pharmacotherapy for, 887–893. See also named agent, e.g. *Bromocriptine*.
bromocriptine, 887–894
cabergoline, 892
pergolide, 891–892
quinogolide, 892
radiotherapy for, 887–888
surgery for, complications from, 888

Prolactinoma(s) *(Continued)*
gonadal function following, 887
hyperprolactinoma following, 887–888
transsphenoidal, 886–887
Prostaglandins, in ovulation, 30
Protein, in cervical mucus, 49
intake of, glomerular hyperfiltration and, 261–262
nephropathy from, 262–264
renal hemodynamics and, 261–262
restriction of, carbohydrate and lipid metabolism and, 265–266
prospective study of, 266, 268
renal function and, 266–268
Puberty, delayed, GH for, 776
GnRH in, 132
oxandrolone for, 776–777
sex steroid therapy for, 776
precocious, GH for, 778
GnRH in, 132

Quinogolide, 892

Radiation, hypergonadotropic amenorrhea from, 180
Radiotherapy, for acromegaly, **693–712**
benefits of, 694–699
clinical response to, 699, 702
complications of, 700–701, 705–707
hyperpituitarism from, 703–704
in non-GH-secreting tumors, 704–705
lifetable analysis of, 695–698
postadenomectomy, 694–696
risks in, 702–705
studies of, 694–695
techniques in, 693–694
tumor response to, 699–700
posttranssphenoid adenomectomy, 688
RAS (renin-angiotensin system), ovarian, 10–11
Renal function, in diabetes mellitus, 261–262, 266–268
Renin-angiotensin system (RAS), ovarian, 10–11
Resistant ovary syndrome, 58
Retinoids, in GH secretion, 489
Retinopathy, diabetic, hypertension-related, 380, 387–388
glycemic control and, 225–27
in gestational diabetes, 447

Saliva, steroids in, in ovulation detection, 51
Sandostatin. See *Octreotide*.
SCFE (slipped femoral epiphysis), in GH therapy, 531
Sex hormone-binding globulin (SHBG), effect of, on plasma androgens, 146
effect on, of obesity, 152
Sex steroids, effect of, on GH release in adults, 804–807
for delayed puberty, 776
GH pulsatility and, 770
GH secretion and, 804–805
in puberty, somatotropic axis and, 770–771
SHGB. See *Sex hormone-binding globulin (SHGB)*.
SIADH. See *Syndrome of inappropriate antidiuretic hormone (SIADH)*.
Skeleton, changes in, acromegalic, **615–632**. See also *Arthropathy*.
Sleep, GH pulsatility and, 786–788
Slipped femoral epiphysis (SCFE), in GH therapy, 531
SmC/IGF–1 test. See *Somatomedin C/insulin-like growth factor–1 (SmC/IGF–1)*.
Sodium, in diabetic patient, total exchangeable increase in, 374–375
tubular resorption increase and, 373
Sodium and fluid retention, in GH therapy, 531
Somatomedin-C/insulin growth factor–1 (IGF–1), generation of, 795
in acromegaly, 806–807
in obesity, 799
Somatomedin C/insulin-like growth factor (SmC/IGF-I) test, for acromegaly, 653–656
plasma, 654–655
urine, 655–656
Somatomedin C test, postadenomectomy, 683
Somatostatin receptors, GH-secreting, on pituitary adenomas, 737–739
Somatostatin analogues, **737–752**. See also *Octreotide*.
effects of, on GH, 784–785
on GhRH, 785–786
Somatostatin (SRHI) test, for acromegaly, 660
Somatotroph cell, in GH secretion, 495–497
Somatotropic axis. See also *Growth hormone (GH)*.
in adults, **783–816**
acromegaly and, 805–807
aging and, 800–804
drugs-induced, 804
gender and sex steroids in, 804–805
glucocorticoid-induced, 804
from lesions, 796
GH deficiency and, 800–804

glucocorticoids and, 804
lesions and, 796
obesity and, 797–800
in puberty, **767–782**
changes in, 771–775
delayed puberty and, 776–777
GH deficiency and, 777–778
GH secretion and, 767–770
GhRH and somatostatin and, 770
insulin-dependent diabetes mellitus and, 778–779
precocious, 778
sex steroids and, 770–771
tall stature and, 777
Sperm, motility of, bromocriptine effect on, 116–117
Spinnbarkeit, of cervical mucus, 46–47
SRHI (somatostatin [SRHI] test), for acromegaly, 660
Steroid hormone receptors, 96
Stress, DKA-hyperosmolar coma syndrome and, 418
HPA axis in, 834–836
Stress system. See also *Hypothalamic-pituitary-adrenal (HPA) axis.*
components and interrelationships of, 834–835
CRH effects on, 834–836
description of, 833
SUs. See *Sulfonylurea (SUs).*
Subcutaneous insulin, administration of, continuous, 308, 310–311
timing of, 288–289
classes of, 286
pharmacokinetics of, 287
pharmacology of, absorption variability and, 288–293
administration timing of, 288–289
bovine and porcine, 290–292
human versus porcine, 292
versus endogenous, 287–288
Sugar, simple, in diabetic diet, 269
Sulfonylurea failure, in NIDDM, **351–370**
insulin-sulfonylurea therapy for, 363–365
insulin therapy for, 355–362
Sulfonylureas (SUs), actions of, pancreatic and extrapancreatic, 338–341
agents available in U.S., 341–343
failure of, **351–370**
initiation of, 343–344
patient selection for, 343
selection of, 342–343
Superovulation, definition of, 76
in treatment of unexplained infertility, 76–78
Surgery. See also *Adenectomy, transsphenoid.*
ambulatory, in diabetic patient, 468–469
emergency, 472–473
endocrine response in, 458–459
metabolic effects of, 458–459
for acromegaly, **669–692**
transsphenoid adenectomy, 673–680
Syndrome of inappropriate antidiuretic hormone (SIADH), **859–875**
causes of, central nervous system disorders, 866–867
drugs, 866–867
malignant tumors, 865–866
pulmonary diseases, 866–867
surgery, 867
clinical forms of, from inappropriate water intake, 865
from vasopressin abnormalities, 864–865, 864–865
differential diagnosis of, criteria for, 869–870
hypo-osmolality of body fluids-associated, 870
impaired urinary dilution in, 870–871
renal, adrenal, thyroid insufficiency and, 871
manifestations of, central pontine myelinolysis, 869
neurologic, 868–869
pathophysiology of, experimental models of, 862–864
in increased water intake and impaired urinary dilution, 862
with desmopressin therapy, 863–864
treatment of, 871–873
demeclocycline for, 873
flurinef in, 873
lithium carbonate for, 873
plasma sodium correction in, 872–873
sodium increase in, 872
water restriction in, 872
water balance regulation and, 859–862
plasma osmolality and sodium concentration homeostasis in, 859–860
thirst regulation in, 861–862
vasopressin secretion in, 860–861
Syndrome X. See *Insulin-resistance syndrome.*

Tall stature, GH in, episodic release of, 777
Terguride, for acromegaly, 726
Testosterone, GH induction and, 773
plasma, insulin levels and, 143–145
TGF-1 (transforming growth factor-1), 6–7
Thirst regulation, in water balance regulation, 861–862
Thrombosis, arterial and venous, DKA-hyperosmolar coma syndrome and, 429–430

Thyroid axis, aging and, hyper- and hypothyroidism in, 925
thyroid replacement in, 926
TSH concentrations in, 925–926
Thyroid gland, dysfunction of, in gestational diabetes, 447
in hypergonadotropism, 175–176
Thyroid hormone, in GH secretion, 492–493
insufficiency of, from GH therapy, 531
Thyroid-stimulating hormone (TSH), in central hypothyroidism, deficiency of, 906–907
secretion of, 909–912
thyrotropin-releasing hormone therapy for, 912
secretion of, 909–912
bioactivity in, 910–912
pituitary hormones and, 909–910
pulsatile, 903–904
thyrotropin-releasing hormone and, 910–912
Thyrotropin-releasing hormone (TRH), in central hypothyroidism, 912–913
in hypothalamic-pituitary lesions, 913
in prolactin stimulation, 106–107, 879
in stimulation tests, for acromegaly, 657–659
postadenomectomy, 682–683
production of, 903
Thyroxine, for central hypothyroidism, 913
TNF-α (tumor necrosis factor-α), 8–9
Transforming growth factor-1 (TGF-1), 6–7
TRH. See *Thyrotropin-releasing hormone (TRH).*
Triglyceride profile, in hyperlipidemia, 403
Tumor necrosis factor-α (TNF-α), 8–9
Tumor(s). See also *Adenoma(s).*
carcinoid, in gigantism, 641
GHRH-producing, 576–581
extracranial, 579–581
GHRH forms in, 582–583
intracranial, 579
pathogenesis of, 576–578
pituitary lesions, 581
GH-secreting, 582
pathogenesis of, 579
Turner syndrome, in female child, GH therapy for, 521–522
Ultrasonography, in LPD diagnosis, 93
in ovulation detection, 51–52
Urinary dilution, in SIADH, 862, 870–871

Vasoactive intestinal peptide (VIP), in prolactin stimulation, 106–107, 878–879
Vasopressin (AVP), aging and, 927–928
response to stimuli and, 927–928
secretion in SIADH, blood volume and pressure and, 860–861
nonosmotic, nonhemodynamic stimuli in, 861
plasma osmolality/sodium and, 860
Very low calorie diets (VLCDs), advantages of, 245–246
behavior therapy with, 246–247
contraindications to, 244
disadvantages of, 246–247
indications for, 244
moderate diet versus, 251
weight cycling from, 248–249
coronary heart disease risk from, 249–251
metabolic effects of, 248–249
Very low density lipoproteins (VLDLs), effect on, of carbohydrates, 252–253
of fats, 255, 258
of omega fatty acids, 260–261
in diabetes mellitus, elevation of, 240
VIP (vasoactive intestinal peptide), 106–107, 878–879
Vision loss, in acromegaly, 644
radiation-induced, in acromegaly, 704–705
VLCDs. See *Very low calorie diets (VLCDs).*
VLDLs. See *Very low density lipoproteins (VLDLs).*

Water intake, inadequate, DKA-hyperosmolar coma syndrome and, 418
restriction of, in SIADH, 872
Wedge resection, for PCOD, 160, 162
Weight, cycling of, on very low calorie diets, 248–251
gain in, in NIDDM, insulin-treated, 361–362
Women, HPA axes of, in endurance training, **817–832**
infertile, GH therapy for, 528, 530